' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Daily subcutaneous Teriparatide injection increased bone mineral density of newly formed bone after tibia distraction osteogenesis, a randomized study.
Wagner, F; Vach, W; Augat, P; Varady, PA; Panzer, S; Keiser, S; Eckardt, H;
Injury. 2019; 50(8): 1478-1482.
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Augat Peter
Keiser Silke
Panzer Stephanie
Varady Patrick Aljoscha

Abstract

Long bone defects are often treated by bone segment transport with the Ilizarov method requiring months spent with fixator mounted until bony consolidation of the newly formed bone. Shortening of consolidation would allow earlier fixator removal and earlier return to work. In pre-clinical studies parathyroid hormone, increased bone mineral density and mechanical properties of regenerate bone formed during distraction osteogenesis. Clinical studies showed that Teriparatide accelerated fracture healing in patients with osteoporotic fracture of the pelvis, hip, wrist and shoulder. We hypothesized that rhPTH(1-34) (Teriparatide) administered to patients who had undergone distraction osteogenesis, would increase mineralization of the regenerate formed during the consolidation phase. Sixteen patients with tibial defects after infection, underwent bone segment transport and at the time of docking the transport segment, were randomized to 8 weeks treatment with daily subcutaneous 0.20-μg Teriparatide injection followed by 8 weeks with no treatment, or to 8 weeks with no treatment followed by 8 weeks with daily subcutaneous 0.20 μg Teriparatide injection. Bone mineral density (BMD) of the regenerate was measured at the time of docking, 8 weeks after docking and 16 weeks after docking with DEXA. Functional evaluation was performed after one year. The design was a cross-over study. Overall BMD increased 0.14 g/cm


Find related publications in this database (Keywords)

PTH
Tibia
Bone defect
Bone regeneration
Bone healing
Distraction osteogenesis